SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 4, 2003
|
CERUS CORPORATION |
||||
|
(Exact name of registrant as specified in its charter) |
||||
|
|
||||
|
Delaware |
|
0-21937 |
|
68-0262011 |
|
(State of jurisdiction) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
2411 Stanwell Drive |
||||
|
(Address of principal executive offices and zip code) |
||||
Registrant’s telephone number, including area code: (925) 288-6000
Item 5. Other Events.
On September 4, 2003, Cerus Corporation (the “Company”) and subsidiaries of Baxter International Inc. announced they are voluntarily halting Phase III trials for their pathogen-inactivated red blood cell program. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 7. Exhibits.
|
Exhibit |
|
Description of Exhibit |
|
99.1 |
|
Press Release, dated September 4, 2003, entitled “Baxter and Cerus halt red blood cell clinical trials for investigational pathogen inactivation system.” |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CERUS CORPORATION |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: September 4, 2003 |
By: |
/s/ Gregory W. Schafer |
|
|
|
|
|
|
Gregory W. Schafer |
|
|
|
|
|
Vice President, Finance and |
|
|
|
|
|
Chief Financial Officer |
|
3
Index to Exhibits
|
Exhibit |
|
Description of Exhibit |
|
99.1 |
|
Press Release, dated September 4, 2003, entitled “Baxter and Cerus halt red blood cell clinical trials for investigational pathogen inactivation system.” |
4